Aminolevulinic Acid Dehydratase
EmergingALAD is the most sensitive biological indicator of lead exposure, beyond its rare role in ALAD-deficiency porphyria.
This enzyme is part of the pathway that makes heme (found in blood). Beyond a very rare inherited disease, its everyday importance is as a sensitive marker of lead exposure, since lead directly blocks this enzyme's function — and some people have a genetic variant that makes them more susceptible to lead's effects.
Aminolevulinic acid dehydratase (ALAD) is a zinc-containing enzyme in the heme synthesis pathway, connecting to the porphobilinogen deaminase discussion (also a heme pathway enzyme) discussed earlier in this biomarker set.
Beyond causing a rare ALAD-deficiency porphyria, this enzyme has a much more common practical use: it's the most sensitive biological indicator of lead exposure, since lead directly inhibits ALAD by displacing zinc at its active site.
Blood ALAD activity is measured as a biomarker of lead exposure; genetic ALAD variants (ALAD1 vs. ALAD2 alleles) also influence individual susceptibility to lead toxicity, with ALAD2 carriers showing higher blood lead levels for a given exposure in multiple studies, an active area of environmental health and pharmacogenetics research.
Confirmed significant lead exposure (via blood lead level, supported by depressed ALAD activity) is managed with source identification/removal and, in severe cases, chelation therapy; ALAD genotype may eventually help identify individuals at higher biological susceptibility to lead's toxic effects for targeted monitoring.
Genetic ALAD variants (ALAD1/ALAD2) influence individual susceptibility to lead toxicity, an active environmental health research area.
- PubMed. Delta-Aminolevulinic acid dehydratase isozymes and lead toxicity.
- PMC. (2007). Lead and δ-Aminolevulinic Acid Dehydratase Polymorphism: Where Does It Lead? A Meta-Analysis.